These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 32460167)

  • 1. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS.
    Engel S; Steffen F; Uphaus T; Scholz-Kreisel P; Zipp F; Bittner S; Luessi F
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 6. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
    Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Calabresi PA; Arnold DL; Sangurdekar D; Singh CM; Altincatal A; de Moor C; Engle B; Goyal J; Deykin A; Szak S; Kieseier BC; Rudick RA; Plavina T
    Mult Scler; 2021 Sep; 27(10):1497-1505. PubMed ID: 33307998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
    J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
    Bjornevik K; Munger KL; Cortese M; Barro C; Healy BC; Niebuhr DW; Scher AI; Kuhle J; Ascherio A
    JAMA Neurol; 2020 Jan; 77(1):58-64. PubMed ID: 31515562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
    Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of radiologic disease activity by serum neurofilaments in MS.
    Uher T; Schaedelin S; Srpova B; Barro C; Bergsland N; Dwyer M; Tyblova M; Vodehnalova K; Benkert P; Oechtering J; Leppert D; Naegelin Y; Krasensky J; Vaneckova M; Kubala Havrdova E; Kappos L; Zivadinov R; Horakova D; Kuhle J; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
    Johnsson M; Stenberg YT; Farman HH; Blennow K; Zetterberg H; Malmeström C; Sandgren S; Rosenstein I; Lycke J; Axelsson M; Novakova L
    Mult Scler; 2024 May; 30(6):664-673. PubMed ID: 38481083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial.
    Janiaud P; Zecca C; Salmen A; Benkert P; Schädelin S; Orleth A; Demuth L; Maceski AM; Granziera C; Oechtering J; Leppert D; Derfuss T; Achtnichts L; Findling O; Roth P; Lalive P; Uginet M; Müller S; Pot C; Hoepner R; Disanto G; Gobbi C; Rooshenas L; Schwenkglenks M; Lambiris MJ; Kappos L; Kuhle J; Yaldizli Ö; Hemkens LG
    Trials; 2024 Sep; 25(1):607. PubMed ID: 39261900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.